CARB-X IS FUNDING AUSTRALIAN-BIOTECH SPEEDX TO DEVELOP A RAPID POINT-OF-CARE DIAGNOSTIC FOR SEXUALLY TRANSMITTED DISEASES CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE

  12 May 2021

CARB-X is awarding SpeeDx, a diagnostics company in Sydney, Australia, up to $1.8 million to develop a rapid test for Chlamydia trachomatis and Neisseria gonorrhoeae, sexually transmitted bacteria that can cause serious infections and that are spreading around the world at alarming rates. SpeeDx is also eligible for $1.9 million in additional funds from CARB-X if the project achieves certain milestones, subject to available funds.

SpeeDx has developed a rapid, molecular test using polymerase chain reaction (PCR) technology called InSignia™, that is able to identify whether an active infection is associated with Chlamydia trachomatis or Neisseria gonorrhoeae.

Further reading: CARB-X
Author(s): Jennifer Robinson
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support kindly provided by

Antimicrobial Resistance Fighter Coalition

CDD VAULT Complexity Simplified





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!